Outsourcing has become a popular trend among
biopharmaceutical developers, allowing them to leverage the expertise / larger
production capacities of CMOs / CDMOs and achieve significant cost and time
related advantages
Roots Analysis is pleased to announce the
publication of its recent study, titled, “Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030.”
The report features an extensive study on the contract
service providers within the biopharmaceutical industry. The study features
in-depth analysis, highlighting the capabilities of a diverse set of
biopharmaceutical CMOs and CDMOs. Amongst other elements, the report includes:
§
A detailed review of the overall landscape of the
biopharmaceutical contract manufacturing market, featuring a comprehensive list
of active CMOs and detailed analysis of the manufacturing service providers
based on a number of parameters.
§
Elaborate profiles of key players that have a diverse range
of capabilities for the development, manufacturing, and packaging of biologics.
§
A detailed discussion
on the key enablers in this domain, including certain niche product classes,
which are likely to have a significant impact on the growth
of the contract services market.
§
A case study on the
growing global biosimilars market, highlighting the opportunities for
biopharmaceutical CMOs and CDMOs.
§
A case study
comparing the key characteristics of large molecule and small molecule drugs, along
with details on the various steps involved in their respective manufacturing
processes.
§
A discussion on
challenges related to in-house manufacturing, featuring a brief overview of the
various parameters that a drug / therapy developer may need to take into
consideration while deciding whether to manufacture its products in-house or
outsource.
§
An analysis of the recent collaborations (signed since
2013) focused on the contract manufacturing of biologics.
§
A detailed analysis of the various mergers and acquisitions
that have taken place in this domain, highlighting the trend in the number of
companies acquired between 2013-2018, along with the geographical distribution
of this activity.
§
An in-depth analysis of more than 490 grants that have been
awarded to research institutes engaged in next generation immune checkpoint
therapy-related projects.
§
An analysis on the recent trends within biopharmaceutical
contract manufacturing industry, highlighting various facility and capability
expansions.
§
A detailed capacity analysis, taking into consideration the
individual development and manufacturing capacities of various stakeholders.
§
A detailed capacity analysis, taking into consideration the
individual development and manufacturing capacities of various stakeholders.
§
A discussion on affiliated trends, key drivers, and
challenges, under a comprehensive SWOT framework.
§
A survey analysis
featuring inputs solicited from various experts who are directly / indirectly
involved in providing CMO services to medical device developers.
§
A detailed market forecast, featuring analysis of the
current and projected future opportunity across key market segments (listed
below)
§
Commonly Outsourced Business Operations
§
Active Pharmaceutical Ingredients (API)
§
Finished Dosage Formulations (FDF)
§
Types of Expression System
§
Mammalian
§
Microbial
§
Others
§
Company Size
§
Small
§
Mid-Sized
§
Large and Very Large
§
Scale of Operation
§
Preclinical
§
Clinical
§
Commercial
§
Key Geographical Region
§
North America
§
Europe
§
Asia-Pacific
§
Rest of the World
The report also features detailed transcripts of
discussions held with the following experts:
§
Astrid Brammer,
Senior Manager Business Development, Richter-Helm Mathias Schmidt (Chief
Executive Officer, ArmaGen)
§
Birgit Schwab, Senior
Manager Strategic Marketing, Rentschler Biotechnologie
§
Christian Bailly,
Director of CDMO, Pierre Fabre
§
Claire Otjes,
Assistant Marketing Manager, Batavia Biosciences
§
David C Cunningham,
Director Corporate Development, Goodwin Biotechnology
§
Dietmar Katinger,
Chief Executive Officer, Polymun Scientific
§
Denis Angioletti,
Chief Commercial Officer, Cerbios-Pharma
§
Jeffrey Hung, Chief
Commercial Officer, Vigene Biosciences
§
Kevin Daley, Director
Pharmaceuticals, Novasep
§
Mark Wright, Site
Head, Grangemouth, Piramal Healthcare
§
Nicolas Grandchamp,
R&D Leader, GEG Tech
§
Raquel Fortunato,
Chief Executive Officer, GenIbet Biopharmaceuticals
§
Sebastian Schuck,
Head of Business Development, Wacker Biotech
§
Stephen Taylor,
Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies
§
Tatjana Buchholz,
Marketing Manager, PlasmidFactory and Marco Schmeer, Project Manager,
PlasmidFactory
§
Tim Oldham, Chief
Executive Officer, Cell Therapies
Key
companies covered in the report
§ 3P Biopharmaceuticals
§ Abzena
§ Albany Molecular Research
§ BioVectra
§ BioXcellence (Boehringer Ingelheim)
§ Celonic
§ Charles River Laboratories
§ ChemPartner
§ Cobra Biologics
§ CordenPharma
§ Cytovance Biologics
§ GE Healthcare
§ Goodwin Biotechnology
§ Grand River Aseptic Manufacturing
§ IDT Biologika
§ KBI BioPharma
§ Kemwell Biopharma
§ LFB Biomanufacturing
§ Meridian Life Science
§ Patheon
§ Pfizer CentreOne
§ PX'Therapeutics
§ Samsung BioLogics
§ Sanofi, CEPiA
§ Thermo Fisher Scientific
§ Vetter Pharma International
For
more information please click on the following link:
Biopharma
Contract Manufacturing Market (3rd Edition), 2019-2030
Other Recent Offerings
1.
Cell
Therapy Manufacturing Market (3rd Edition),
2019-2030
2.
Antibody
Contract Manufacturing Market, 2020-2030
3.
China Biopharmaceutical Contract
Manufacturing
Market, 2020-2030
4.
Peptide
Therapeutics: Contract API Manufacturing Market, 2020-2030
About Roots Analysis
Roots Analysis is one of the fastest growing market
research companies, sharing fresh and independent perspectives in the
bio-pharmaceutical industry. The in-depth research, analysis and insights are driven
by an experienced leadership team which has gained many years of significant
experience in this sector. If you’d like help with your growing business needs,
get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
